Population Pharmacokinetic Analysis for Imipenem-Relebactam in Healthy Volunteers and Patients With Bacterial Infections by Pratik Bhagunde, Parul Patel, Mallika Lala, Kenny Watson, William Copalu, Ming Xu, Pooja Kulkarni, Katherine Young, Matthew L. Rizk

Connect to this object online.

Understanding effect site pharmacology of uprifosbuvir, a hepatitis C virus nucleoside inhibitor: Case study of a multidisciplinary modeling approach in drug development by Paul van den Berg, Wei Gao, Maurice J. Ahsman, Leticia Arrington, Filippos Kesisoglou, Randy Miller, Teun M. Post, Matthew L. Rizk

Connect to this object online.

Population pharmacokinetic/pharmacodynamic assessment of imipenem/cilastatin/relebactam in patients with hospital‐acquired/ventilator‐associated bacterial pneumonia by Munjal Patel, Francesco Bellanti, Naveen M. Daryani, Nadia Noormohamed, David W. Hilbert, Katherine Young, Pooja Kulkarni, William Copalu, Ferdous Gheyas, Matthew L. Rizk

Connect to this object online.

Molnupiravir: Mechanism of action, clinical, and translational science by Brian M. Maas, Julie Strizki, Randy R. Miller, Sushma Kumar, Michelle Brown, Matthew G. Johnson, Mickie Cheng, Carisa De Anda, Matthew L. Rizk, Julie A. Stone

Connect to this object online.

Population pharmacokinetics of molnupiravir in adults with COVID‐19: Lack of clinically important exposure variation across individuals by Sébastien Bihorel, Youfang Cao, Akshita Chawla, Ruthie Birger, Brian M. Maas, Wei Gao, Stefan Roepcke, Susanne Sardella, Rebecca Humphrey, Sindhuri Kondragunta, Bhuvana Jayaraman, Monika Martinho, Wendy Painter, George Painter, Wayne Holman, Carisa De Anda, Michelle L. Brown, Matthew G. Johnson, Amanda Paschke, Matthew L. Rizk, Julie A. Stone

Connect to this object online.